$6.05
-0.05-0.82%
Last update: Nov 10, 7:01 PM
Emergent BioSolutions Inc
EBSNYSE
Emergent BioSolutions fell 43.9% from $10.88 to $6.10, behind the S&P 500's +9.8%. Its worst day was Aug 6 (−29.6%), and its low came Aug 11 at $4.45.
Nov 11, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Emergent BioSolutions closed at its highest level of the year, 27.8% above where the year started.
+5.7% · S&P 500 −0.3%
Emergent BioSolutions shares fell 12.7%, while the S&P 500 rose 0.3%.
Story events cover the past 12 months · Times ET
−12.7% · S&P 500 +0.3%
EPS of $-0.43 missed the $0.32 estimate on $148.7M revenue (est. $216.5M); FY revenue guidance of $720.0M–$760.0M against the $1.2B consensus.
−26.6%, on 5M shares, the year's heaviest volume · S&P 500 −0.5%
EPS of $0.21 beat the $-0.25 estimate on $156.1M revenue (est. $157.4M); Q2 revenue guidance of $170.0M–$185.0M against the $182.2M consensus.
+2.9% · S&P 500 +0.3%
EPS of $0.60 beat the $0.11 estimate on $234.3M revenue (est. $179.4M); Q3 revenue guidance of $110.0M–$130.0M against the $209.0M consensus.
−29.6%, the year's worst day · S&P 500 −0.2%
Emergent BioSolutions shares rose 14.4%, while the S&P 500 rose 0.7%.
+14.4%, the year's best day · S&P 500 +0.7%
Emergent BioSolutions shares fell 11.1%, while the S&P 500 fell 1.1%.
−11.1% · S&P 500 −1.1%
EPS of $-0.36 beat the $-0.40 estimate on $110.0M revenue (est. $123.2M); FY revenue guidance of $600.0M–$645.0M against the $656.2M consensus.
−3.0% · S&P 500 +0.3%
Where it ended: a close of $6.10 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.46, revenue est. $167.8M).
Nothing in the past 12 months.
All EBS dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for EBS and SPY from Benzinga historical bars. Not investment advice.
